A new era in CNS drug delivery: Crossing the blood brain barrier
Advances in neuroscience are reshaping our understanding of the brain and opening new frontiers in how we diagnose, treat, and ultimately prevent neurological...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA combines in-depth industry knowledge and cutting-edge analytics to evaluate issues being litigated and debated in the healthcare sector. Our industry knowledge enables us to explain, for example, the nuances of provider reimbursement or the patient incentives created by high deductible health insurance plans, and our economic, statistical, accounting, investigative, and finance skills—as well as our familiarity with key healthcare datasets—equips CRA to provide rigorous, defensible analyses tailored to the specific facts of a litigation or regulatory dispute.
Our experts have broad and deep experience in the healthcare sector including hospitals, physician practices, health insurance and health benefit plans, ACOs, PBMs, wholesalers, pharmacies, pharmaceuticals and biologicals, medical devices, clinical laboratories, dialysis facilities, ambulance transport, nursing homes, and home healthcare.
Advances in neuroscience are reshaping our understanding of the brain and opening new frontiers in how we diagnose, treat, and ultimately prevent neurological...
2025 has been a year of progress in the rare disease (RD) space. At CRA, we continue to leverage our cross-functional expertise in strategy, policy, analytics,...
